The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act

RATIONALE: Lemborexant (LEM) is a dual orexin receptor antagonist (DORA) approved in multiple countries including the USA, Japan, Canada, Australia, and several Asian countries for the treatment of insomnia in adults. As a compound with central nervous system activity, it is important to understand...

Descripción completa

Detalles Bibliográficos
Autores principales: Moline, Margaret, Asakura, Shoji, Beuckman, Carsten, Landry, Ishani, Setnik, Beatrice, Ashworth, Judy, Henningfield, Jack E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006052/
https://www.ncbi.nlm.nih.gov/pubmed/36749354
http://dx.doi.org/10.1007/s00213-023-06320-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006052/
https://www.ncbi.nlm.nih.gov/pubmed/36749354
http://dx.doi.org/10.1007/s00213-023-06320-y

Ejemplares similares